Skip to Content

Late-breaking from ASH22 – Let’s keep the standard consolidation therapy with HDC-ASCT for PCNSL patients

The first results from the MATRix/IELSG43 trial indicate that standard consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation results in significantly better outcomes when compared to non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top